Condition 1: Rheumatoid Arthritis. Condition 2: Rheumatoid Arthritis. Condition 3: Rheumatoid Arthritis. Seropositive rheumatoid arthritis Other rheumatoid arthritis Juvenile arthritis
Conditions
Interventions
Intervention 1: Patients in intervention group will receive daily one 100 mg capsule of Coenzyme Q10 with meal for two months. Intervention 2: Patients in control group will receive daily one capsule
Treatment - Drugs
Placebo
Patients in intervention group will receive daily one 100 mg capsule of Coenzyme Q10 with meal for two months
Patients in control group will receive daily one capsule of placebo with meal for two months
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Disease diagnosis based on ACR criteria by expert; Fixed type and dose of drugs one month before intervention to the end of the study; Under treatment with DMARDs (Hydroxychloroquine, Prednisone, Methotrexate, Sulfasalazine, and ...); Patients with moderate and severe disease; Catching RA disease at least six months ago; Age between 18 to 65 years; Consent to participate in the study Exclusion criteria: Simultaneously participate in trials of other investigators; Pregnancy or the decision to become pregnant during the study period; Breastfeeding; Taking contraceptive drugs; Consumption of antioxidant supplements (A, C, E); Consumption of omega-3 fatty acids; Having liver, kidney, thyroid, diabetes, or infectious disease; Taking anticoagulants such as warfarin; Smoking or repeated exposure to smoking; Drug addiction; Not wanting to continue; Less than 70% adherence
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malondialdehyde (MDA). Timepoint: At baseline and 2 months after intervention. Method of measurement: Spectrophotometry.;Matrix metalloproteinase 1 (MMP-1). Timepoint: At baseline and 2 months after intervention. Method of measurement: MMP-1 kit.;Matrix metalloproteinase 3 (MMP-3). Timepoint: At baseline and 2 months after intervention. Method of measurement: MMP-3 kit.;Total antioxidant capacity (TAC). Timepoint: At baseline and 2 months after intervention. Method of measurement: TAC kit.;Interleukin 6 (IL-6). Timepoint: At baseline and 2 months after intervention. Method of measurement: IL-6 kit.;Tumor necrosis factor alpha (TNF-a). Timepoint: At baseline and 2 months after intervention. Method of measurement: TNF-a kit.;Health status. Timepoint: At baseline and 2 months after intervention. Method of measurement: Questionnaire.;Disease activity. Timepoint: At baseline and 2 months after intervention. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| High density lipoprotein (HDL). Timepoint: At baseline and 2 months after intervention. Method of measurement: HDL kit.;Triglyceride (TG). Timepoint: At baseline and 2 months after intervention. Method of measurement: TG kit.;Cholesterol. Timepoint: At baseline and 2 months after intervention. Method of measurement: Cholesterol kit.;Low density lipoprotein (LDL). Timepoint: At baseline and 2 months after intervention. Method of measurement: Calculate with the friedewald equation.;Body mass index (BMI). Timepoint: At baseline and 2 months after intervention. Method of measurement: Calculation. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed